Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Key Inclusion Criteria:

1. Has AF or flutter (paroxysmal or persistent), not felt to be secondary to areversible cause, and an indication for indefinite anticoagulation treatment asdescribed in the protocol

2. Meets one of the following:

3. CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Thromboembolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and OralAnticoagulant (OAC) naïve or

4. CHA2DS2-VA score ≥3 or

5. CHA2DS2-VA score of 2 and at least 1 enrichment criteria as described in theprotocol

6. Must have an International Normalization Ratio (INR) <2.5 at the time ofrandomization if taking warfarin or another Vitamin K Antagonist (VKA)

Key Exclusion Criteria:

1. Has a mechanical heart valve prosthesis (Note: transcatheter aortic valvereplacement is not an exclusion)

2. Has known moderate-to-severe mitral stenosis

3. Has had successful ablation therapy or Left Atrial Appendage (LAA)occlusion/exclusion, or planned ablation or LAA occlusion/exclusion as described inthe protocol

4. Had an ischemic stroke within 2 days prior to randomization

5. Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m^2 within 30 daysprior to randomization or on dialysis or expected to be started as described in theprotocol

6. Has a history of central nervous system bleeding within 30 days prior torandomization

Note: Other protocol-defined Inclusion/ Exclusion criteria apply